KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $8.05, for a total transaction of $80,500.00. Following the completion of the sale, the insider now owns 2,876,027 shares in the company, valued at approximately $23,152,017.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Holdings A/S Novo also recently made the following trade(s):
- On Wednesday, September 13th, Holdings A/S Novo sold 25,900 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $8.02, for a total transaction of $207,718.00.
- On Friday, September 15th, Holdings A/S Novo sold 176,647 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $7.21, for a total transaction of $1,273,624.87.
KalVista Pharmaceuticals, Inc. (NASDAQ KALV) traded down 13.11% on Friday, hitting $6.96. 162,624 shares of the company were exchanged. KalVista Pharmaceuticals, Inc. has a one year low of $6.09 and a one year high of $10.65. The stock has a 50 day moving average price of $8.20 and a 200 day moving average price of $7.83. The firm’s market cap is $67.60 million.
KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.08. The company had revenue of $0.10 million during the quarter. KalVista Pharmaceuticals had a negative net margin of 4,191.47% and a negative return on equity of 57.41%. On average, equities research analysts forecast that KalVista Pharmaceuticals, Inc. will post ($2.94) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://ledgergazette.com/2017/09/16/kalvista-pharmaceuticals-inc-kalv-major-shareholder-holdings-as-novo-sells-10000-shares-of-stock.html.
An institutional investor recently bought a new position in KalVista Pharmaceuticals stock. Eventide Asset Management LLC bought a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned approximately 1.01% of KalVista Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 75.66% of the stock is currently owned by institutional investors.
Several brokerages have commented on KALV. ValuEngine upgraded shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 2nd. BTIG Research initiated coverage on shares of KalVista Pharmaceuticals in a research note on Thursday, August 31st. They set a “buy” rating and a $18.00 price objective on the stock.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.